BRIEF-Retrophin Initiates Pivotal Phase 3 Clinical Trial Of Sparsentan For The Treatment Of Focal Segmental Glomerulosclerosis
April 03, 2018 at 08:09 AM EDT
* RETROPHIN INITIATES PIVOTAL PHASE 3 CLINICAL TRIAL OF SPARSENTAN FOR THE TREATMENT OF FOCAL SEGMENTAL GLOMERULOSCLEROSIS Source text for Eikon: Further company coverage: